Investment analysts at William Blair issued their FY2029 earnings per share estimates for shares of Neumora Therapeutics in a ...

Neuroscience company Neumora Therapeutics (NMRA) announced today that its experimental treatment for depression, Navacaprant, ...

Neumora Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -74.98%. The profit margin, also known as the revenue ratio or gross profit ...

Neumora Therapeutics ( NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a ...

Neumora Therapeutics Inc (NMRA) stock saw a modest uptick, ending the day at $2.17 which represents a slight increase of $0.20 or 10.15% from the prior close of $1.97. The stock opened at $2.23 and ...

BofA analyst Geoff Meacham lowered the firm’s price target on Neumora Therapeutics (NMRA) to $7 from $22 and keeps a Buy rating on the shares.

Mizuho keeps an Outperform rating on Neumora Therapeutics (NMRA) after the company announced negative first Phase 3 KOASTAL-1 ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) saw some unusual options trading on Monday. Stock traders acquired ...

Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NMRA stock, giving a Buy rating today.Don't Miss Our New Year's ...

Neumora Therapeutics (NMRA) crashed after its Phase 3 study for its lead asset navacaprant in major depressive disorder ...

Neumora Therapeutics Inc. (NASDAQ: NMRA) nosedived by more than 80 percent during pre-market trading following disappointing ...

Check the time stamp on this data. Updated AI-Generated Signals for Neumora Therapeutics Inc. (NMRA) available here: NMRA.